

December 19, 2017

ONO enters into Collaboration Agreement with Schrödinger Inc.

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director and CEO, Gyo Sagara; “ONO”) announced today that it entered into a collaboration agreement with Schrödinger, Inc. (New York, United States; President & Chief Executive Officer, Ramy Farid, PhD; Schrödinger) a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods.

Under the terms of the collaboration agreement Schrödinger will work together to leverage ONO’s strength and Schrödinger’s computational drug discovery platform in the design of novel small molecules against therapeutic targets selected by ONO. Schrödinger will receive research funding plus milestone payments from Ono. Additional details and financial terms of the collaboration were not disclosed.

“We have a high regard for Schrödinger’s computational drug discovery method,” said Hiromu Habashita, Corporate Officer, and Executive Director of Discovery & Research of ONO. “We are excited to work with Schrödinger on identifying and developing the next generation of innovative treatments.”

“ONO has been a long-time user of our software, and we’re very pleased to deepen our engagement with them,” said Ramy Farid, Schrödinger’s President and CEO. “We look forward to further enable ONO’s efforts to design innovative new drugs that promise to have an important impact on the lives of patients.”

About Schrödinger

Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services to accelerate and increase the efficiency of drug discovery for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and was a cofounder of leading biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Schrödinger’s investors include David E. Shaw and Bill Gates. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. Hundreds of peer-reviewed scientific publications by Schrödinger scientists are frequently among the most heavily cited in their fields. Founded in 1990, Schrödinger has over 300 employees and operations in the United States, Europe, Japan, and India, as well as business partners in China and Korea. For more information, please visit www.schrodinger.com.

Contact

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

public_relations@ono.co.jp